Vero cell-adapted SARS-CoV-2 strain shows increased viral growth through furin-mediated efficient spike cleavage

  • Shohei Minami
    Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
  • Tomohiro Kotaki
    Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
  • Yusuke Sakai
    Department of Pathology, National Institute of Infectious Diseases, Tokyo, Japan
  • Shinya Okamura
    Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, Japan
  • Shiho Torii
    Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
  • Chikako Ono
    Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
  • Daisuke Motooka
    Department of Infection Metagenomics, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
  • Rina Hamajima
    Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
  • Ryotaro Nouda
    Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
  • Jeffery A. Nurdin
    Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
  • Moeko Yamasaki
    Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
  • Yuta Kanai
    Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
  • Hirotaka Ebina
    Virus Vaccine Group, BIKEN Innovative Vaccine Research Alliance Laboratories, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Osaka, Japan
  • Yusuke Maeda
    Laboratory of Viral Dynamism Research, Research Institute for Microbial Diseases Osaka University, Osaka, Japan
  • Toru Okamoto
    Institute for Advanced Co-creation Studies, Research Institute for Microbial Diseases Osaka University, Osaka, Japan
  • Taro Tachibana
    Cell Engineering Corporation, Osaka, Japan
  • Yoshiharu Matsuura
    Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan
  • Takeshi Kobayashi
    Department of Virology, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan

説明

<jats:title>ABSTRACT</jats:title> <jats:sec> <jats:title/> <jats:p> Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) utilizes several host proteases to cleave the spike (S) protein to enter host cells. SARS-CoV-2 S protein is cleaved into S1 and S2 subunits by furin, which is closely involved in the pathogenicity of SARS-CoV-2. However, the effects of the modulated protease cleavage activity due to S protein mutations on viral replication and pathogenesis remain unclear. Herein, we serially passaged two SARS-CoV-2 strains in Vero cells and characterized the cell-adapted SARS-CoV-2 strains <jats:italic>in vitro</jats:italic> and <jats:italic>in vivo</jats:italic> . The adapted strains showed high viral growth, effective S1/S2 cleavage of the S protein, and low pathogenicity compared with the wild-type strain. Furthermore, the viral growth and S1/S2 cleavage were enhanced by the combination of the Δ68–76 and H655Y mutations using recombinant SARS-CoV-2 strains generated by the circular polymerase extension reaction. The recombinant SARS-CoV-2 strain, which contained the mutation of the adapted strain, showed increased susceptibility to the furin inhibitor, suggesting that the adapted SARS-CoV-2 strain utilized furin more effectively than the wild-type strain. Pathogenicity was attenuated by infection with effectively cleaved recombinant SARS-CoV-2 strains, suggesting that the excessive cleavage of the S proteins decreases virulence. Finally, the high-growth-adapted SARS-CoV-2 strain could be used as the seed for a low-cost inactivated vaccine; immunization with this vaccine can effectively protect the host from SARS-CoV-2 variants. Our findings provide novel insights into the growth and pathogenicity of SARS-CoV-2 in the evolution of cell-cell transmission. </jats:p> </jats:sec> <jats:sec> <jats:title>IMPORTANCE</jats:title> <jats:p> The efficacy of the S protein cleavage generally differs among the SARS-CoV-2 variants, resulting in distinct viral characteristics. The relationship between a mutation and the entry of SARS-CoV-2 into host cells remains unclear. In this study, we analyzed the sequence of high-growth Vero cell-adapted SARS-CoV-2 and factors determining the enhancement of the growth of the adapted virus and confirmed the characteristics of the adapted strain by analyzing the recombinant SARS-CoV-2 strain. We successfully identified mutations Δ68-76 and H655Y, which enhance viral growth and the S protein cleavage by furin. Using recombinant viruses enabled us to conduct a virus challenge experiment <jats:italic>in vivo</jats:italic> . The pathogenicity of SARS-CoV-2 introduced with the mutations Δ68-76, H655Y, P812L, and Q853L was attenuated in hamsters, indicating the possibility of the attenuation of excessive cleaved SARS-CoV-2. These findings provide novel insights into the infectivity and pathogenesis of SARS-CoV-2 strains, thereby significantly contributing to the field of virology. </jats:p> </jats:sec>

収録刊行物

参考文献 (62)*注記

もっと見る

関連プロジェクト

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ